Works by Jianying Zhou

Results: 220
    1
    2
    3
    4
    5
    6

    NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression.

    Published in:
    Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-54651-x
    By:
    • Reddy, Tejaswini;
    • Puri, Akshjot;
    • Guzman-Rojas, Liliana;
    • Thomas, Christoforos;
    • Qian, Wei;
    • Zhou, Jianying;
    • Zhao, Hong;
    • Mahboubi, Bijan;
    • Oo, Adrian;
    • Cho, Young-Jae;
    • Kim, Baek;
    • Thaiparambil, Jose;
    • Rosato, Roberto;
    • Martinez, Karina Ortega;
    • Chervo, Maria Florencia;
    • Ayerbe, Camila;
    • Giese, Noah;
    • Wink, David;
    • Lockett, Stephen;
    • Wong, Stephen
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16

    Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies.

    Published in:
    BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02865-z
    By:
    • Hu, Xingsheng;
    • Zhang, Shucai;
    • Ma, Zhiyong;
    • Feng, Jifeng;
    • Wu, Lin;
    • Lv, Dongqing;
    • Zhou, Jianying;
    • Zhang, Xiaodong;
    • Liu, Li;
    • Yu, Qitao;
    • Liao, Wangjun;
    • Zhang, Yiping;
    • Wang, Xiang;
    • Cheng, Ying;
    • Niu, Hongrui;
    • Wang, Ziping;
    • Wang, Dong;
    • Huang, Cheng;
    • Liu, Chunling;
    • Zhao, Hui
    Publication type:
    Article
    17

    Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.

    Published in:
    BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-022-02692-8
    By:
    • Shi, Yuankai;
    • Zhou, Jianying;
    • Zhao, Yanqiu;
    • Zhu, Bo;
    • Zhang, Liangming;
    • Li, Xingya;
    • Fang, Jian;
    • Shi, Jianhua;
    • Zhuang, Zhixiang;
    • Yang, Sheng;
    • Wang, Donglin;
    • Yu, Huiqing;
    • Zhang, Longzhen;
    • Zheng, Rongsheng;
    • Greco, Michael;
    • Wang, Tingting
    Publication type:
    Article
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40

    P382: A CLINICAL PROGNOSTIC SCORING SYSTEM FOR ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION OUTCOMES IN ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME‐POSITIVE ACUTE LYMPHOBLASTIC LEUKAEMIA.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000968436.02695.11
    By:
    • Wang, Song;
    • Zhou, Jianying;
    • Zhu, Xiao‐Lu;
    • Fu, Hai‐Xia;
    • Shi, Ling‐Ling;
    • He, Yun;
    • Wang, Feng‐Rong;
    • Zhang, Yuan‐Yuan;
    • Mo, Xiao‐Dong;
    • Yan, Chen‐Hua;
    • Kong, Yuan;
    • Han, Wei;
    • Wang, Jing‐Zhi;
    • Wang, Yu;
    • Chen, Huan;
    • Chen, Yu‐Hong;
    • Zhao, Xiang‐Yu;
    • Chang, Ying‐Jun;
    • Xu, Lan‐Ping;
    • Liu, Kai‐Yan
    Publication type:
    Article
    41
    42
    43
    44
    45
    46
    47

    Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a‐rearranged acute myeloid leukemia.

    Published in:
    Cancer (0008543X), 2025, v. 131, n. 2, p. 1, doi. 10.1002/cncr.35717
    By:
    • Wang, Lulu;
    • Chen, Yuxiu;
    • Zang, Mengtong;
    • Zhou, Jianying;
    • Xiao, Mengyu;
    • Fu, Haixia;
    • Mo, Xiaodong;
    • Wang, Fengrong;
    • Han, Wei;
    • Zhang, Yuanyuan;
    • Yan, Chenhua;
    • Wang, Zhidong;
    • Han, Tingting;
    • Lv, Meng;
    • Chen, Huan;
    • Chen, Yuhong;
    • Chen, Yao;
    • Wang, Jingzhi;
    • Wang, Yu;
    • Xu, Lanping
    Publication type:
    Article
    48
    49
    50